Biosimilar and Interchangeable Biologics: Strategic Elements

by Sarfaraz K. Niazi
Even the most established companies have made mistakes when developing biosimilar products. For example, not appreciating the future threats to intellectual property caused a biosimilar product development plan to fail after millions have been spent. Additional pitfalls include, not anticipating the next line of improved products, better formulations, delivery systems and the possibility that the dosing and indications can themselves be patented, thus making the choice of products to develop a major exercise. This two-volume set examines how to choose the right product to develop, how to meander around the legal fireworks and secure a viable commercial presence.

Product Details